Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
60actual
Sites
41
Countries
Australia, Canada, Israel +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-06 | actual | When the study began enrolling |
| Primary completion | 2026-01-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-26 | actual | The whole study's end, after follow-up |
| First posted | 2020-03-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Spinal Cord Injury (SCI)
Interventions
- Drug: Elezanumab — also filed as ABT-555
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFUpper Extremity Motor Score (UEMS)
measured 52 Weeks
Number of Participants Experiencing Adverse Events
measured Up to approximately 91 Weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed